Bristol-Myers Ends Hepatitis C Drug Development

«Pg_Titre»
Microbicides Development Programme: Engaging the Community in the Standard of Care Debate Coinfection by Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus in Injecting Drug Users 86 Paulo, Brazil; 4) Universidade Federal da Bahia, Salvador, Bahia, Brazil; 5) Bristol-Myers … Retrieve Doc

Bristol-Myers Ends Hepatitis C Drug Development
Bristol-Myers ends hepatitis C drug development (AP)—Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a … View Doc

Bristol-Myers Ends Hepatitis C Drug Development
Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.The New York company said Thursday that it decided … Read News

June 2012 IPELINE ENDS
ENDS is produced by the University of Massachusetts Medical Drug Name: Daclatasvir Manufacturer: Bristol-Myers Squibb Indication: Chronic hepatitis C *Designates specialty drug. Agents in Clinical Development … Fetch Doc

OTI0057 0809 CorpHepAllianceBro3:Layout 1
Bristol-Myers Squibb Molli Conti is the current Associate Director of the relationships with HIV, hepatitis and drug dependence patient advocacy groups As the Director of Sales Training & Market Development for Three Rivers Pharmaceuticals, Chris has been involved in the Hepatitis C arena the past 6 … Doc Retrieval

When A Person Is Infected With hepatitis C, The Virus Often …
Among those at greatest risk for hepatitis C are: Hemophiliacs, intravenous drug users cirrhosis is established, the rate of development of HCC is 1-4 percent per year. (National Institutes of Health Consensus Statement on Hepatitis C used by the interferons we with Hep C know. Bristol-Myers … View Document

IPELINE ENDS
ENDS Non-Specialty Specialty Drug Name: Boceprevir Manufacturer: Merck Indication: Hepatitis C Co-developed by Pfizer and Bristol-Myers Squibb exceptional depth and experience in the development and implementation … Fetch Document

Oracle Life Sciences User Group Meeting
Jansen E. Lim, Bristol-Myers Squib Abstract Oracle is the platform of choice for the majority of were diabetes, hepatitis C, breast cancer, pediatric asthma, congestive heart failure (CHF Tularik, as a small molecule drug discovery and development company, has … Doc Retrieval

Bristol-Myers Ends Hepatitis C Drug Development
Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure. … Read News

HCV Advocate Newsletter March 2003
Chronic hepatitis C and B in the U.S. today. Drug patents, to encourage innovation and to pay for the costs of drug development. brand-name patent ends. When this happens, the patent- … Doc Retrieval

Medivir
With Bristol-Myers Squibb. Pre-clinical development completed drug” from Johnson & Johnson Market registration of Lipsovir® towards ends 2008 Medivir’s goal: A profitable pharmaceutical company with its own research and sales E Some of our collaboration partners OSTEOPOROSIS HEPATITIS C … Get Document

Generation Of Replication-Competent Hepatitis B Virus …
Pharmaceutical Research Institute, Bristol-Myers Squibb, Wallingford, Connecticut 06492 environment, the interior of the capsid, and also fuel the development of new anti-HBV drug screens. Human hepatitis B virus (HBV ends (see below); the longest of them appeared close in size to … Fetch Doc

Day 1: Sunday, May 2
Title: RNAi and Development in C. elegans 10.05 – 10.40 AM Keynote Lecture on human viral hepatitis infection 5.30 – 5.55 PM: Ronald Scheule, PhD. Research Investigator, Bristol-Myers Squibb, Princeton, NJ Title: Validation of Novel Drug Targets using RNAi … View Full Source

June 2012 ENews
Explore new treatments for patients: Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C Medgenics Inc. has received orphan drug designation for its Biopump technology to treat hepatitis D. registration ends June 27. More. Osteogenesis … Content Retrieval

Ultrasensitive Genotypic Detection Of Antiviral Resistance In …
Bristol-Myers Squibb Research and Development, Wallingford, Connecticut,1 and Bristol sof 60°C, unless indicated otherwise in Table S1 in the supplemental material. The 5 ends dynamics in the selection of drug resistance in HIV and hepatitis B and C … Content Retrieval

Monitor Gene Therapy
8 Walker, M.A. (1999) Hepatitis C virus: an overview of current approaches and progress. Drug Discov. proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J. Mol. Biol. 289, 385–396 Michael A. Walker Bristol-Myers Squibb opportunities for rational drug development. … Fetch Doc